 Pantheris Sales and TigereyeTM Expansion Drive 91 Year-Over-Year Revenue Growth REDWOOD CITY, CA ACCESSWIRE August 10, 2021 Avinger, Inc. NASDAQ:AVGR, a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease PAD, today reported results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Revenue increased 91 year-over-year to 2.8 million, fueled by Pantheris sales growth and new Tigereye CTO sales Record Pantheris SV revenue reflects strong market adoption of Avingers small-vessel catheter, primarily used in below-the-knee BTK applications Image-guided CTO revenue increased 114 year-over-year, driven by Tigereye launch at more than 40 sites Gross margin increased to 36 as Avinger scales its operations Opened more than 30 new Lumivascular accounts in the last 12 months on increased market demand for Avingers highly differentiated technology Filed 510k in June to expand Pantheris clinical indication for treatment of in-stent restenosis ISR Filed 510k in August for the Lightbox 3 next generation imaging console Maintained strong cash position of 26.7 million at June 30, 2021, anticipated to fund sales force expansion, new product development and clinical plans through 2022 Jeff Soinski, Avingers President and CEO, commented, Avingers 2021 growth momentum continued in the second quarter as we delivered strong revenue gains for both our Pantheris atherectomy and image-guided CTO product lines and procedural volume improving in the first half of the year. 